Skip to main content

Table 1 Patient characteristics

From: Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events

Patient No./Age/Sex/Race*

Diagnosis* & Duration

Time on drug†

Concomitant medication‡

Alcohol units/wk

1/46/M/WB

PsA 20 years

2 days (On re-challenge)

Piroxicam, temazepam, paracetamol and dextropropoxyphene.

8 units

2/35/F/WB

RA 3 months

14 days

Diclofenac, paracetamol and dextropropoxyphene.

None

3/35/M/BB

ReA ~3 months

31 days

Diclofenac, flucloxacillin, paracetamol with dihydrocodeine

8 units

4/50/M/WB

PsA 28 months

>270 days

Felodipine, lansoprazole.

>30 units

5/33/F/BB

RA 23 months

~14 days

Celecoxib

None

6/30/F/WB

RA <3 months

5 days

Diclofenac. Methylprednisolone 120 mg intra-muscularly before starting sufasalazine.

None

7/64/F/BB

RA 10 years

~12 days

Chlorpheniramine, lisinopril, aspirin, cetirizine. Inhaled steroids & β-agonists

None

8/37/F/BB

RA 7 months

~42 days

Rofecoxib, prednisolone, paracetamol with dihydrocodeine, aspirin, folic acid.

None

9/45/F/WB

?RA 6 months

~17 days

Sertraline

None

10/48/F/BB

RA 3 months

10 days

Lansoprazole, tramadol, stemetil, thyroxine, rofecoxib, co-proxamol

None

  1. * WB – White British, BB – Black British of African or Carribean descent. PsA: Psoriatic arthritis. RA: rheumatoid arthritis. ReA: reactive arthritis.
  2. † For episode related to adverse event. ‡ At the time of adverse event.